Breaking News

Cellares’ Cell Shuttle Receives FDA AMT Designation

This acknowledges the Cell Shuttle’s ability to automate and reliably manufacture cell therapies.

By: Rachel Klemovitch

Assistant Editor

Cellares, an Integrated Development and Manufacturing Organization (IDMO), announced that its Cell Shuttle has received the Advanced Manufacturing Technology (AMT) designation by the FDA’s Center for Biologics Evaluation and Research (CBER).  This designation acknowledges the Cell Shuttle’s ability to automate and reliably manufacture cell therapies and represents a significant step forward in the advanced manufacturing of cell therapies. As a result of this designation, developers leverag...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters